Display options
Cite
Zeiler FA, Gillman LM, Teitelbaum J, et al. Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics. Case Rep Crit Care. 2014;2014:139342doi: 10.1155/2014/139342.
Zeiler, F. A., Gillman, L. M., Teitelbaum, J., & West, M. (2014). Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics. Case reports in critical care, 2014139342. https://doi.org/10.1155/2014/139342
Zeiler, F A, et al. "Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics." Case reports in critical care vol. 2014 (2014): 139342. doi: https://doi.org/10.1155/2014/139342
Zeiler FA, Gillman LM, Teitelbaum J, West M. Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics. Case Rep Crit Care. 2014;2014:139342. doi: 10.1155/2014/139342. Epub 2014 Dec 04. PMID: 25544901; PMCID: PMC4273533.
Copy Download .nbib Format: NLM
Share it on

Case Rep Crit Care. 2014;2014:139342. doi: 10.1155/2014/139342. Epub 2014 Dec 04.

Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics.

Case reports in critical care

F A Zeiler, L M Gillman, J Teitelbaum, M West

Affiliations

  1. Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada R3A 1R9.
  2. Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada R3A 1R9 ; Section of General Surgery, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada R3A 1R9.
  3. Section of Neurocritical Care, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4 ; Section of Neurology, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4.

PMID: 25544901 PMCID: PMC4273533 DOI: 10.1155/2014/139342

Abstract

Background. Tromethamine (THAM) has been demonstrated to reduce intracranial pressure (ICP). Early consideration for THAM may reduce the need for other measures for ICP control. Objective. To describe 4 cases of early THAM therapy for ICP control and highlight the potential to avoid TH and paralytics and achieve reduction in sedation and hypertonic/hyperosmotic agent requirements. Methods. We reviewed the charts of 4 patients treated with early THAM for ICP control. Results. We identified 2 patients with aneurysmal subarachnoid hemorrhage (SAH) and 2 with traumatic brain injury (TBI) receiving early THAM for ICP control. The mean time to initiation of THAM therapy was 1.8 days, with a mean duration of 5.3 days. In all patients, after 6 to 12 hours of THAM administration, ICP stability was achieved, with reduction in requirements for hypertonic saline and hyperosmotic agents. There was a relative reduction in mean hourly hypertonic saline requirements of 89.1%, 96.1%, 82.4%, and 97.0% for cases 1, 2, 3, and 4, respectively, comparing pre- to post-THAM administration. Mannitol, therapeutic hypothermia, and paralytics were avoided in all patients. Conclusions. Early administration of THAM for ICP control could potentially lead to the avoidance of other ICP directed therapies. Prospective studies of early THAM administration are warranted.

References

  1. J Neurosurg. 1993 Jan;78(1):54-9 - PubMed
  2. Neurosurg Clin N Am. 2013 Jul;24(3):457-67 - PubMed
  3. Neurocrit Care. 2014 Oct;21(2):332-44 - PubMed
  4. Drugs. 1998 Feb;55(2):191-224 - PubMed
  5. Best Pract Res Clin Anaesthesiol. 2007 Dec;21(4):517-38 - PubMed
  6. Crit Care. 2007;11(5):231 - PubMed
  7. J Neurosurg. 2010 May;112(5):1095-104 - PubMed
  8. Stroke. 2007 Nov;38(11):3084-94 - PubMed
  9. J Neurosurg Anesthesiol. 1994 Jul;6(3):201-8 - PubMed
  10. Crit Care. 2014 Apr 17;18(2):R75 - PubMed

Publication Types